Moderna has partnered with OpenAI to integrate GPTs into its operations. The move marks a significant shift in how Moderna approaches drug discovery and development, as AI-powered language models are now being utilized across various facets of the company's workflow.

Why it’s notable:

• Moderna first partnered with OpenAI in early 2023, actively integrating ChatGPT Enterprise across its teams. An initial two month testing phase revealed significant adoption as, Moderna reported that 750 personalized versions of OpenAI’s ChatGPT, known as GPTs had been formed throughout the organization.Each user had an average of 120 weekly conversations using the platform and  40% of weekly active users had created GPTs tailored to specific team requirements

• Now, the full integration of OpenAI's GPTs is reshaping operations, from research to communication and development. 3,000 workers at Moderna will now have access to ChatGPT Enterprise, which is based on GPT-4, OpenAI's most sophisticated language model. Moderna said that company may be able to surpass its goal of releasing 15 new products in the next five years if AI is further integrated into more of its operations. 

How Moderna implements GPT chat technology: 

Two notable cases highlight the breadth of Moderna's AI integration: its Dose ID and Policy Chatbot solutions.

• With Dose ID, Moderna utilizes AI-powered chat interfaces to facilitate seamless communication between healthcare providers and patients, offering personalized support and guidance on vaccine administration and safety protocols. 

• Similarly, through its Policy Chat bot, Moderna strengthens its compliance procedures by making it easier for employees to get quick answers about internal policies without needing to search through hundreds of documents. 

• Various teams across Moderna boast 100% adoption of ChatGPT enterprise solutions and enabling efficiencies that allow them to focus their time and attention to truly driving impact for patients. These cases underscore Moderna's commitment to leveraging AI-driven solutions to enhance patient care, streamline operations, and drive impactful advancements in its pipeline. 

POV: This move not only highlights the company's commitment to innovation but also signals a broader shift toward AI-driven solutions in biotechnology, potentially paving the way for more efficient drug development pipelines and personalized medicine approaches.

• Moderna's adoption of GPTs reflects a broader trend within the pharmaceutical sector, where AI technologies are increasingly becoming indispensable tools for research and development. As competition intensifies and the demand for novel therapies grows, companies are turning to AI to gain a competitive edge, optimize resource allocation, and expedite decision-making processes.

• Moderna's embrace of GPTs prompts both excitement and caution. While AI holds the promise of revolutionizing drug discovery and development, there are concerns surrounding data privacy, algorithmic bias, and the ethical implications of AI-generated content. As pharmaceutical companies increasingly rely on AI for critical decision-making, ensuring transparency, accountability, and regulatory compliance will be paramount.

• Additionally, the integration of AI technologies may necessitate upskilling existing workforce and redefining traditional roles within the industry, prompting a broader conversation about the future of work in the age of AI. Nonetheless, the potential benefits of AI-driven innovation in biotechnology are immense, offering new possibilities for addressing unmet medical needs and advancing human health.